REFERENCES
1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249-54.
2. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76:e159-240.
3. Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655-68.
4. Guigui SA, Torres C, Escolar E, Mihos CG. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review. J Thorac Dis. 2022;14:2309-25.
5. Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017;389:1253-67.
6. Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res. 2015;105:397-408.
8. Ingles J, Burns C, Barratt A, Semsarian C. Application of genetic testing in hypertrophic cardiomyopathy for preclinical disease detection. Circ Cardiovasc Genet. 2015;8:852-9.
10. Neubauer S, Kolm P, Ho CY, et al; HCMR Investigators. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll Cardiol. 2019;74:2333-45.
11. Watkins H. Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. Circulation. 2021;143:2415-7.
12. Chung H, Kim J, Min P, et al. Different contribution of sarcomere and mitochondria related gene mutations to hypertrophic cardiomyopathy. J Am Coll Cardiol. 2018;71:A901.
13. Wijnker PJM, Sequeira V, Kuster DWD, Velden JV. Hypertrophic cardiomyopathy: a vicious cycle triggered by sarcomere mutations and secondary disease hits. Antioxid Redox Signal. 2019;31:318-58.
14. Sequeira V, Bertero E, Maack C. Energetic drain driving hypertrophic cardiomyopathy. FEBS Lett. 2019;593:1616-26.
15. Morimoto S, Yanaga F, Minakami R, Ohtsuki I. Ca2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol. 1998;275:C200-7.
16. van Dijk SJ, Paalberends ER, Najafi A, et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail. 2012;5:36-46.
17. Fraysse B, Weinberger F, Bardswell SC, et al. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol. 2012;52:1299-307.
18. Sequeira V, Wijnker PJ, Nijenkamp LL, et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res. 2013;112:1491-505.
19. Schuldt M, Johnston JR, He H, et al. Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes. J Mol Cell Cardiol. 2021;150:77-90.
20. Koda M, Takemura G, Okada H, et al. Nuclear hypertrophy reflects increased biosynthetic activities in myocytes of human hypertrophic hearts. Circ J. 2006;70:710-8.
21. Nollet EE, Schuldt M, Sequeira V, et al. Integrating clinical phenotype with multiomics analyses of human cardiac tissue unveils divergent metabolic remodeling in genotype-positive and genotype-negative patients with hypertrophic cardiomyopathy. Circ Genom Precis Med. 2024;17:e004369.
22. Szyguła-Jurkiewicz B, Szczurek-Wasilewicz W, Osadnik T, et al. Oxidative stress markers in hypertrophic cardiomyopathy. Medicina (Kaunas). 2021;58:31.
23. Stathopoulou K, Wittig I, Heidler J, et al. S-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure. FASEB J. 2016;30:1849-64.
24. Wilder T, Ryba DM, Wieczorek DF, Wolska BM, Solaro RJ. N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015;309:H1720-30.
25. Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-82.
26. Sequeira V, Najafi A, McConnell M, et al. Synergistic role of ADP and Ca2+ in diastolic myocardial stiffness. J Physiol. 2015;593:3899-916.
27. McNamara JW, Li A, Lal S, et al. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. PLoS One. 2017;12:e0180064.
28. Toepfer CN, Garfinkel AC, Venturini G, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation. 2020;141:828-42.
29. McNamara JW, Li A, Dos Remedios CG, Cooke R. The role of super-relaxed myosin in skeletal and cardiac muscle. Biophys Rev. 2015;7:5-14.
30. Vander Roest AS, Liu C, Morck MM, et al. Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state. Proc Natl Acad Sci U S A. 2021;118:e2025030118.
31. Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018;115:E8143-52.
32. Stewart MA, Franks-Skiba K, Chen S, Cooke R. Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers. Proc Natl Acad Sci U S A. 2010;107:430-5.
33. Landim-Vieira M, Ma W, Song T, et al. Cardiac troponin T N-domain variant destabilizes the actin interface resulting in disturbed myofilament function. Proc Natl Acad Sci U S A. 2023;120:e2221244120.
34. Sequeira V, Maack C, Reil GH, Reil JC. Exploring the connection between relaxed myosin states and the anrep effect. Circ Res. 2024;134:117-34.
35. Witjas-Paalberends ER, Güçlü A, Germans T, et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res. 2014;103:248-57.
36. Witjas-Paalberends ER, Piroddi N, Stam K, et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res. 2013;99:432-41.
37. Piroddi N, Witjas-Paalberends ER, Ferrara C, et al. The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM. J Gen Physiol. 2019;151:18-29.
38. Güçlü A, Knaapen P, Harms HJ, et al. Disease stage-dependent changes in cardiac contractile performance and oxygen utilization underlie reduced myocardial efficiency in human inherited hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017;10:e005604.
39. Parbhudayal RY, Harms HJ, Michels M, van Rossum AC, Germans T, van der Velden J. Increased myocardial oxygen consumption precedes contractile dysfunction in hypertrophic cardiomyopathy caused by pathogenic TNNT2 gene variants. J Am Heart Assoc. 2020;9:e015316.
40. Timmer SA, Germans T, Brouwer WP, et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011;13:1283-9.
42. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093-129.
43. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab. 2009;297:E578-91.
44. Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994;267:H742-50.
45. Gnaiger E. Mitochondrial pathways and respiratory control: an introduction to OXPHOS analysis. 5th ed. Bioenergetics communications; 2020.2.
46. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci U S A. 2005;102:808-13.
47. Cortassa S, Aon MA, Marbán E, Winslow RL, O’Rourke B. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J. 2003;84:2734-55.
48. Bertero E, Maack C. Calcium signaling and reactive oxygen species in mitochondria. Circ Res. 2018;122:1460-78.
49. Griffiths EJ, Rutter GA. Mitochondrial calcium as a key regulator of mitochondrial ATP production in mammalian cells. Biochim Biophys Acta. 2009;1787:1324-33.
50. Grover-McKay M, Schwaiger M, Krivokapich J, Perloff JK, Phelps ME, Schelbert HR. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13:317-24.
51. Shimonagata T, Nishimura T, Uehara T, et al. Discrepancies between myocardial perfusion and free fatty acid metabolism in patients with hypertrophic cardiomyopathy. Nucl Med Commun. 1993;14:1005-13.
52. Chen SL, Uehara T, Morozumi T, Yamagami H, Kusuoka H, Nishimura T. Myocardial metabolism of 123I-BMIPP in patients with hypertrophic cardiomyopathy: assessment by radial long-axis SPET. Nucl Med Commun. 1995;16:336-43.
53. Nishimura T, Nagata S, Uehara T, et al. Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography. Ann Nucl Med. 1996;10:71-8.
54. Matsuo S, Nakamura Y, Takahashi M, Mitsunami K, Kinoshita M. Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeled beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ischemia. Jpn Circ J. 1998;62:167-72.
55. Tadamura E, Kudoh T, Hattori N, et al. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med. 1998;39:390-6. Available from: https://jnm.snmjournals.org/content/jnumed/39/3/390.full.pdf [accessed 10 June 2025].
56. Ohtsuki K, Sugihara H, Kuribayashi T, et al. Impairment of BMIPP accumulation at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. J Nucl Med. 1999;40:2007-13. Available from: https://jnm.snmjournals.org/content/jnumed/40/12/2007.full.pdf [accessed 10 June 2025].
57. Shimizu M, Ino H, Okeie K, et al. Cardiac dysfunction and long-term prognosis in patients with nonobstructive hypertrophic cardiomyopathy and abnormal 123I-15- (p-Iodophenyl)-3(R,S)-methylpentadecanoic acid myocardial scintigraphy. Cardiology. 2000;93:43-9.
58. Ishida Y, Nagata S, Uehara T, et al. Clinical analysis of myocardial perfusion and metabolism in patients with hypertrophic cardiomyopathy by single photon emission tomography and positron emission tomography. J Cardiol. 2001;37 Suppl 1:121-8.
59. Takeda T, Wu J, Fumikura Y, et al. Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI. Eur J Nucl Med Mol Imaging. 2003;30:966-73.
60. Zhao C, Shuke N, Okizaki A, et al. Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cardiomyopathies: by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. Ann Nucl Med. 2003;17:541-8.
61. Narita M, Kurihara T. Is I-123-beta-methyl-p-iodophenyl-methylpentadecanoic acid imaging useful to evaluate asymptomatic patients with hypertrophic cardiomyopathy? Int J Cardiovasc Imaging. 2003;19:499-510.
62. Goodman MM, Kirsch G, Knapp FF Jr. Synthesis and evaluation of radioiodinated terminal p-iodophenyl-substituted alpha- and beta-methyl-branched fatty acids. J Med Chem. 1984;27:390-7.
63. Knapp FF Jr, Ambrose KR, Goodman MM. New radioiodinated methyl-branched fatty acids for cardiac studies. Eur J Nucl Med. 1986;12 Suppl:S39-44.
64. Sai E, Shimada K, Yokoyama T, et al. Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. Heart Vessels. 2017;32:166-74.
65. Nollet EE, Duursma I, Rozenbaum A, et al. Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration. Eur Heart J. 2023;44:1170-85.
66. Tuunanen H, Kuusisto J, Toikka J, et al. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol. 2007;14:354-65.
68. Coats CJ, Heywood WE, Virasami A, et al. Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circ Genom Precis Med. 2018;11:e001974.
69. Schuldt M, Pei J, Harakalova M, et al. Proteomic and functional studies reveal detyrosinated tubulin as treatment target in sarcomere mutation-induced hypertrophic cardiomyopathy. Circ Heart Fail. 2021;14:e007022.
70. Previs MJ, O’Leary TS, Morley MP, et al. Defects in the proteome and metabolome in human hypertrophic cardiomyopathy. Circ Heart Fail. 2022;15:e009521.
71. Wang W, Wang J, Yao K, et al. Metabolic characterization of hypertrophic cardiomyopathy in human heart. Nat Cardiovasc Res. 2022;1:445-61.
72. Ranjbarvaziri S, Kooiker KB, Ellenberger M, et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation. 2021;144:1714-31.
73. Luiken JJ, Chanda D, Nabben M, Neumann D, Glatz JF. Post-translational modifications of CD36 (SR-B2): Implications for regulation of myocellular fatty acid uptake. Biochim Biophys Acta. 2016;1862:2253-8.
74. Nienaber CA, Gambhir SS, Mody FV, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation. 1993;87:1580-90.
75. Perrone-Filardi P, Bacharach SL, Dilsizian V, Panza JA, Maurea S, Bonow RO. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. Am J Cardiol. 1993;72:199-204.
76. Tadamura E, Tamaki N, Matsumori A, et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med 1996;37:572-7. Available from https://www.proquest.com/openview/ecb3bf2940477270f6d138ccae7f5b0a/1?pq-origsite=gscholar&cbl=40808 [accessed 10 June 2025].
77. Ishiwata S, Maruno H, Senda M, Toyama H, Nishiyama S, Seki A. Myocardial blood flow and metabolism in patients with hypertrophic cardiomyopathy--a study with carbon-11 acetate and positron emission tomography. Jpn Circ J. 1997;61:201-10.
78. Uehara T, Ishida Y, Hayashida K, et al. Myocardial glucose metabolism in patients with hypertrophic cardiomyopathy: assessment by F-18-FDG PET study. Ann Nucl Med. 1998;12:95-103.
79. Aoyama R, Takano H, Kobayashi Y, et al. Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography. PLoS One. 2017;12:e0188479.
80. Ritterhoff J, Young S, Villet O, et al. Metabolic remodeling promotes cardiac hypertrophy by directing glucose to aspartate biosynthesis. Circ Res. 2020;126:182-96.
81. Ritterhoff J, Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat Rev Cardiol. 2023;20:812-29.
82. Murashige D, Jang C, Neinast M, et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science. 2020;370:364-8.
83. Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Webb-Peploe MM. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Br Heart J. 1986;56:544-53.
84. Cannon RO III, Schenke WH, Maron BJ, et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:53-62.
85. Thompson DS, Naqvi N, Juul SM, et al. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J. 1980;44:488-98.
86. Cannon RO III, McIntosh CL, Schenke WH, Maron BJ, Bonow RO, Epstein SE. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation. 1989;79:766-75.
87. Unno K, Isobe S, Izawa H, et al. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J. 2009;30:1853-62.
88. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002;109:357-62.
89. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res. 1999;42:246-53.
90. Algül S, Schuldt M, Manders E, et al. EGFR/IGF1R signaling modulates relaxation in hypertrophic cardiomyopathy. Circ Res. 2023;133:387-99.
91. Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med. 2018;5:68.
92. Jørgenrud B, Jalanko M, Heliö T, et al. The metabolome in finnish carriers of the MYBPC3-Q1061X mutation for hypertrophic cardiomyopathy. PLoS One. 2015;10:e0134184.
93. Schuldt M, van Driel B, Algül S, et al. Distinct metabolomic signatures in preclinical and obstructive hypertrophic cardiomyopathy. Cells. 2021;10:2950.
94. Jansen M, Schuldt M, van Driel BO, et al. Untargeted metabolomics identifies potential hypertrophic cardiomyopathy biomarkers in carriers of MYBPC3 founder variants. Int J Mol Sci. 2023;24:4031.
95. Jansen M, Schmidt AF, Jans JJM, et al. Circulating acylcarnitines associated with hypertrophic cardiomyopathy severity: an exploratory cross-sectional study in MYBPC3 founder variant carriers. J Cardiovasc Transl Res. 2023;16:1267-75.
96. Deidda M, Noto A, Pasqualucci D, et al. The Echocardiographic parameters of systolic function are associated with specific metabolomic fingerprints in obstructive and non-obstructive hypertrophic cardiomyopathy. Metabolites. 2021;11:787.
97. Wolter NL, LeClair MJ, Chin MT. Plasma metabolomic profiling of hypertrophic cardiomyopathy patients before and after surgical myectomy suggests postoperative improvement in metabolic function. BMC Cardiovasc Disord. 2021;21:617.
98. Zhang K, Yuan Z, Wang S, Zhao S, Cui H, Lai Y. The abnormalities of free fatty acid metabolism in patients with hypertrophic cardiomyopathy, a single-center retrospective observational study. BMC Cardiovasc Disord. 2024;24:312.
99. Bae H, Lam K, Jang C. Metabolic flux between organs measured by arteriovenous metabolite gradients. Exp Mol Med. 2022;54:1354-66.
100. Voros G, Ector J, Garweg C, et al. Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling. Circ Heart Fail. 2018;11:e004953.
101. Pal N, Acharjee A, Ament Z, et al. Metabolic profiling of aortic stenosis and hypertrophic cardiomyopathy identifies mechanistic contrasts in substrate utilization. FASEB J. 2024;38:e23505.
102. Bedi KC Jr, Snyder NW, Brandimarto J, et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016;133:706-16.
103. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698-705.
104. Roos A, Doornbos J, Luyten PR, Oosterwaal LJ, van der Wall EE, den Hollander JA. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging. 1992;2:711-9.
105. Sieverding L, Jung WI, Breuer J, et al. Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. Am J Cardiol. 1997;80:34A-40A.
106. Jung WI, Sieverding L, Breuer J, et al.
107. Valkovič L, Clarke WT, Schmid AI, et al. Measuring inorganic phosphate and intracellular pH in the healthy and hypertrophic cardiomyopathy hearts by in vivo 7T 31P-cardiovascular magnetic resonance spectroscopy. J Cardiovasc Magn Reson. 2019;21:19.
108. Dass S, Cochlin LE, Suttie JJ, et al. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. Eur Heart J. 2015;36:1547-54.
109. Pesta D, Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. In: Palmeira CM, Moreno AJ, editors. Mitochondrial bioenergetics. Totowa: Humana Press; 2012. pp. 25-58.
110. Maron BJ, Ferrans VJ, Henry WL, et al. Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH): light and electron microscopic findings. Circulation. 1974;50:436-46.
111. Maron BJ, Ferrans VJ, Roberts WC. Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. Am J Pathol. 1975;79:387-434.
112. Wilding JR, Joubert F, de Araujo C, et al. Altered energy transfer from mitochondria to sarcoplasmic reticulum after cytoarchitectural perturbations in mice hearts. J Physiol. 2006;575:191-200.
113. Ramaccini D, Montoya-Uribe V, Aan FJ, et al. Mitochondrial function and dysfunction in dilated cardiomyopathy. Front Cell Dev Biol. 2020;8:624216.
114. Kohlhaas M, Sequeira V, Parikh S, et al. Mitochondrial reactive oxygen species cause arrhythmias in hypertrophic cardiomyopathy. bioRxiv. 2024:2024.10.02.616214.
115. Paar V, Haslinger M, Krombholz-Reindl P, et al. Hypertrophic cardiomyopathy is characterized by alterations of the mitochondrial calcium uniporter complex proteins: insights from patients with aortic valve stenosis versus hypertrophic obstructive cardiomyopathy. Front Pharmacol. 2023;14:1264216.
116. Pisano A, Cerbelli B, Perli E, et al. Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage ischemic heart failure. Cardiovasc Pathol. 2016;25:103-12.
117. Hinton A Jr, Claypool SM, Neikirk K, et al. Mitochondrial structure and function in human heart failure. Circ Res. 2024;135:372-96.
118. Kavantzas NG, Lazaris ACH, Agapitos EV, et al. Histological assessment of apoptotic cell death in cardiomyopathies. Pathology. 2000;32:176-80.
119. Ikon N, Ryan RO. Cardiolipin and mitochondrial cristae organization. Biochim Biophys Acta Biomembr. 2017;1859:1156-63.
120. Meddeb M, Koleini N, Binek A, et al. Myocardial ultrastructure of human heart failure with preserved ejection fraction. Nat Cardiovasc Res. 2024;3:907-14.
121. Čunátová K, Vrbacký M, Puertas-Frias G, et al. Mitochondrial translation is the primary determinant of secondary mitochondrial complex I deficiencies. iScience. 2024;27:110560.
122. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114:1151-8.
123. Abraham MR, Bottomley PA, Dimaano VL, et al. Creatine kinase adenosine triphosphate and phosphocreatine energy supply in a single kindred of patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:861-6.
124. Mekhfi H, Veksler V, Mateo P, Maupoil V, Rochette L, Ventura-Clapier R. Creatine kinase is the main target of reactive oxygen species in cardiac myofibrils. Circ Res. 1996;78:1016-27.
125. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280-8.
126. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol. 1996;52:273-80.
127. Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562-9.
128. Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014;74:971-80.
129. Coats CJ, Pavlou M, Watkinson OT, et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 2019;4:230-5.
130. van Driel B, Schoonvelde S, Borodzicz-Jazdzuk S, et al. Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation. Eur Heart J. 2024;45:ehae666. 2032.
131. Maron MS, Mahmod M, Abd Samat AH, et al. Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2024;83:2037-48.
132. George CH, Mitchell AN, Preece R, Bannister ML, Yousef Z. Pleiotropic mechanisms of action of perhexiline in heart failure. Expert Opin Ther Pat. 2016;26:1049-59.
133. Gehmlich K, Dodd MS, Allwood JW, et al. Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. Mol Biosyst. 2015;11:564-73.
134. Feldman JM, Frishman WH, Aronow WS. Ninerafaxstat in the treatment of diabetic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy. Cardiol Rev. 2024:10.1097.
135. Fetterman JL, Sammy MJ, Ballinger SW. Mitochondrial toxicity of tobacco smoke and air pollution. Toxicology. 2017;391:18-33.
136. Watson WD, Green PG, Lewis AJM, et al. Retained metabolic flexibility of the failing human heart. Circulation. 2023;148:109-23.
137. Pfeiffer K, Gohil V, Stuart RA, et al. Cardiolipin stabilizes respiratory chain supercomplexes. J Biol Chem. 2003;278:52873-80.
138. Milenkovic D, Misic J, Hevler JF, et al. Preserved respiratory chain capacity and physiology in mice with profoundly reduced levels of mitochondrial respirasomes. Cell Metab. 2023;35:1799-1813.e7.
139. Yin H, Zhu M. Free radical oxidation of cardiolipin: chemical mechanisms, detection and implication in apoptosis, mitochondrial dysfunction and human diseases. Free Radic Res. 2012;46:959-74.
140. Nakamura K, Kusano KF, Matsubara H, et al. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail. 2005;11:117-23.
141. Christiansen LB, Dela F, Koch J, Hansen CN, Leifsson PS, Yokota T. Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015;308:H1237-47.
142. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171:2029-50.
143. Paratz ED, Mundisugih J, Rowe SJ, Kizana E, Semsarian C. Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon? Can J Cardiol. 2024;40:777-88.
144. Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617-21.
145. Hartman JJ, Hwee DT, Robert-Paganin J, et al. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res. 2024;3:1003-16.
146. Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64:14142-52.
147. Lehman SJ, Crocini C, Leinwand LA. Targeting the sarcomere in inherited cardiomyopathies. Nat Rev Cardiol. 2022;19:353-63.
148. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759-69.
149. Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78:2518-32.
150. Saberi S, Cardim N, Yamani M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation. 2021;143:606-8.
151. Wheeler MT, Olivotto I, Elliott PM, et al. Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial. JAMA Cardiol. 2023;8:240-7.
152. Hegde SM, Claggett BL, Wang X, et al; SEQUOIA-HCM Investigators. Impact of aficamten on echocardiographic cardiac structure and function in symptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2024;84:1789-802.
153. Maron MS, Masri A, Nassif ME, et al; SEQUOIA-HCM Investigators. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024;390:1849-61.
154. Giudicessi JR, Alsidawi S, Geske JB, et al. Genotype influences mavacamten responsiveness in obstructive hypertrophic cardiomyopathy. Mayo Clin Proc. 2024;99:341-3.
155. Nollet EE, Westenbrink BD, de Boer RA, Kuster DWD, van der Velden J. Unraveling the genotype-phenotype relationship in hypertrophic cardiomyopathy: obesity-related cardiac defects as a major disease modifier. J Am Heart Assoc. 2020;9:e018641.
156. Robertson J, Lindgren M, Schaufelberger M, et al. Body mass index in young women and risk of cardiomyopathy: a long-term follow-up study in sweden. Circulation. 2020;141:520-9.
157. Robertson J, Schaufelberger M, Lindgren M, et al. Higher body mass index in adolescence predicts cardiomyopathy risk in midlife: term follow-up among Swedish men. Circulation. 2019;140:117-25.
158. Wasserstrum Y, Barriales-Villa R, Fernández-Fernández X, et al. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. Eur Heart J. 2019;40:1671-7.
159. Park JB, Kim DH, Lee H, et al. Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2020;27:1849-57.
160. Claes GR, van Tienen FH, Lindsey P, et al. Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. Eur Heart J. 2016;37:1815-22.
161. Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62:449-57.
162. Fumagalli C, Maurizi N, Day SM, et al; SHARE Investigators. Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy. JAMA Cardiol. 2020;5:65-72.
163. Yu SQ, Shi K, Li Y, et al. The impact of diabetes mellitus on cardiac function assessed by magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Cardiovasc Diabetol. 2024;23:293.
164. Harper AR, Goel A, Grace C, et al; HCMR Investigators. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021;53:135-42.
165. Ingles J, Burns C, Bagnall RD, et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circ Cardiovasc Genet. 2017;10:e001620.
166. Nollet EE, Algül S, Goebel M, et al. Western diet triggers cardiac dysfunction in heterozygous Mybpc3-targeted knock-in mice: a two-hit model of hypertrophic cardiomyopathy. J Mol Cell Cardiol Plus. 2023;6:100050.
167. Feria AE, Kott AE, Becker JR. Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity. Open Heart. 2021;8:e001560.
168. Schoonvelde SAC, Nollet EE, Zwetsloot PP, et al. Genotype-negative hypertrophic cardiomyopathy: exploring the role of cardiovascular risk factors in disease expression. Int J Cardiol. 2025;437:133444.
169. Ommen SR, Ho CY, Asif IM, et al; Peer Review Committee Members. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the american heart association/american college of cardiology joint committee on clinical practice guidelines. Circulation. 2024;149:e1239-311.
170. Cavigli L, Olivotto I, Fattirolli F, et al. Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: ready for prime time. Eur J Prev Cardiol. 2021;28:1093-9.
171. Anker SD, Butler J, Filippatos G, et al; EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61.
172. Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149:204-16.
173. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632-44.
174. Osataphan S, Macchi C, Singhal G, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight. 2019;4:e123130.
175. Aglan A, Fath AR, Eldaly AS, et al. Impact of sodium-glucose cotransporter 2 inhibitors on mortality in hypertrophic cardiomyopathy. JACC Adv. 2024;3:100843.
176. Wijnker PJM, Dinani R, van der Laan NC, et al. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors. Cardiovasc Res. 2024;120:301-17.
